SiSaf

SiSaf is a biopharmaceutical company founded in 2006 by Dr. Suzanne Saffie-Siebert, a nanoparticle scientist with over 25 years of experience in the pharmaceutical industry.

Dr. Saffie-Siebert's journey as an entrepreneur is deeply connected to her scientific expertise. She is the inventor of the company's proprietary Bio-Courier technology, a drug delivery platform based on silicon-stabilized liposomes. This technology is designed to overcome the challenges of delivering RNA-based therapies to specific cells in the body.

SiSaf's business model is focused on the development of RNA therapeutics for rare genetic disorders. The company leverages its Bio-Courier platform to create a pipeline of treatments for these diseases. SiSaf operates in the biopharmaceutical market, collaborating with other companies and research institutions to advance its therapeutic programs. The company generates revenue through a combination of research and development collaborations, licensing agreements, and the future commercialization of its products.

The company's core product is its Bio-Courier technology. This platform utilizes silicon-stabilized liposomes to encapsulate and protect RNA molecules, ensuring their safe and effective delivery to target cells. The benefits of this technology include improved stability, reduced toxicity, and enhanced therapeutic efficacy of RNA-based drugs. A key selling point of the Bio-Courier platform is its potential to enable the development of treatments for a wide range of rare genetic diseases that are currently untreatable.

Keywords: biopharmaceutical, drug delivery, RNA therapeutics, rare genetic disorders, silicon-based, liposomes, gene therapy, nanomedicine, drug development, clinical trials